471 related articles for article (PubMed ID: 16142373)
21. Expression of E-cadherin and alpha-, beta-, gamma-catenins in patients with bladder cancer: identification of gamma-catenin as a new prognostic marker of neoplastic progression in T1 superficial urothelial tumors.
Clairotte A; Lascombe I; Fauconnet S; Mauny F; Félix S; Algros MP; Bittard H; Kantelip B
Am J Clin Pathol; 2006 Jan; 125(1):119-26. PubMed ID: 16483000
[TBL] [Abstract][Full Text] [Related]
22. Expression of classic cadherins type I in urothelial neoplastic progression.
Rieger-Christ KM; Cain JW; Braasch JW; Dugan JM; Silverman ML; Bouyounes B; Libertino JA; Summerhayes IC
Hum Pathol; 2001 Jan; 32(1):18-23. PubMed ID: 11172290
[TBL] [Abstract][Full Text] [Related]
23. Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumors.
Bringuier PP; Umbas R; Schaafsma HE; Karthaus HF; Debruyne FM; Schalken JA
Cancer Res; 1993 Jul; 53(14):3241-5. PubMed ID: 8324734
[TBL] [Abstract][Full Text] [Related]
24. Proliferative activity is the most significant predictor of recurrence in noninvasive papillary urothelial neoplasms of low malignant potential and grade 1 papillary carcinomas of the bladder.
Pich A; Chiusa L; Formiconi A; Galliano D; Bortolin P; Comino A; Navone R
Cancer; 2002 Aug; 95(4):784-90. PubMed ID: 12209722
[TBL] [Abstract][Full Text] [Related]
25. Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder.
Shariat SF; Kim JH; Ayala GE; Kho K; Wheeler TM; Lerner SP
J Urol; 2003 Mar; 169(3):938-42. PubMed ID: 12576817
[TBL] [Abstract][Full Text] [Related]
26. Histologic tumor growth pattern is significantly associated with disease-related survival in muscle-invasive transitional cell carcinoma of the urinary bladder.
Krüger S; Noack F; Böhle A; Feller AC
Oncol Rep; 2004 Sep; 12(3):609-13. PubMed ID: 15289845
[TBL] [Abstract][Full Text] [Related]
27. Decreased expression of galectin-3 predicts tumour recurrence in pTa bladder cancer.
Kramer MW; Kuczyk MA; Hennenlotter J; Serth J; Schilling D; Stenzl A; Merseburger AS
Oncol Rep; 2008 Dec; 20(6):1403-8. PubMed ID: 19020721
[TBL] [Abstract][Full Text] [Related]
28. [Multivariate analysis of recurrence in T1 bladder transitional cell carcinoma].
Zhang J; Zeng L; Li GZ; Yang XY; Xia TL; Na YQ; Guo YL
Zhonghua Zhong Liu Za Zhi; 2003 Sep; 25(5):475-7. PubMed ID: 14575574
[TBL] [Abstract][Full Text] [Related]
29. Assessment of the transcriptional activity of p53 improves the prediction of recurrence in superficial transitional cell carcinoma of the bladder.
Dekairelle AF; Tombal B; Cosyns JP; Gala JL
Clin Cancer Res; 2005 Jul; 11(13):4724-32. PubMed ID: 16000567
[TBL] [Abstract][Full Text] [Related]
30. Expressions of E-cadherin and exon v6-containing isoforms of CD44 and their prognostic values in human transitional cell carcinoma.
Hong RL; Pu YS; Hsieh TS; Chu JS; Lee WJ
J Urol; 1995 Jun; 153(6):2025-8. PubMed ID: 7538603
[TBL] [Abstract][Full Text] [Related]
31. Expression of the CD44 cell adhesion molecule in urinary bladder transitional cell carcinoma.
Ross JS; del Rosario AD; Bui HX; Kallakury BV; Okby NT; Figge J
Mod Pathol; 1996 Aug; 9(8):854-60. PubMed ID: 8871928
[TBL] [Abstract][Full Text] [Related]
32. N-cadherin as a novel prognostic marker of progression in superficial urothelial tumors.
Lascombe I; Clairotte A; Fauconnet S; Bernardini S; Wallerand H; Kantelip B; Bittard H
Clin Cancer Res; 2006 May; 12(9):2780-7. PubMed ID: 16675571
[TBL] [Abstract][Full Text] [Related]
33. The prognostic value of P-cadherin in non-muscle-invasive bladder cancer.
Wang P; Lin SL; Zhang LH; Li Z; Liu Q; Gao JX; Liu DM; Bo JJ; Huang YR
Eur J Surg Oncol; 2014 Mar; 40(3):255-9. PubMed ID: 24429027
[TBL] [Abstract][Full Text] [Related]
34. Prognostic significance of E-cadherin protein expression in pathological stage I-III endometrial cancer.
Mell LK; Meyer JJ; Tretiakova M; Khramtsov A; Gong C; Yamada SD; Montag AG; Mundt AJ
Clin Cancer Res; 2004 Aug; 10(16):5546-53. PubMed ID: 15328195
[TBL] [Abstract][Full Text] [Related]
35. Value of clusterin immunoreactivity as a predictive factor in muscle-invasive urothelial bladder carcinoma.
Krüger S; Mahnken A; Kausch I; Feller AC
Urology; 2006 Jan; 67(1):105-9. PubMed ID: 16413343
[TBL] [Abstract][Full Text] [Related]
36. Low E-cadherin expression in bladder cancer at the transcriptional and protein level provides prognostic information.
Popov Z; Gil-Diez de Medina S; Lefrere-Belda MA; Hoznek A; Bastuji-Garin S; Abbou CC; Thiery JP; Radvanyi F; Chopin DK
Br J Cancer; 2000 Jul; 83(2):209-14. PubMed ID: 10901372
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of hypoxia-inducible factor 1alpha overexpression as a predictor of tumour recurrence and progression in superficial urothelial bladder carcinoma.
Theodoropoulos VE; Lazaris AC; Kastriotis I; Spiliadi C; Theodoropoulos GE; Tsoukala V; Patsouris E; Sofras F
BJU Int; 2005 Feb; 95(3):425-31. PubMed ID: 15679808
[TBL] [Abstract][Full Text] [Related]
38. Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma.
Chatterjee SJ; Datar R; Youssefzadeh D; George B; Goebell PJ; Stein JP; Young L; Shi SR; Gee C; Groshen S; Skinner DG; Cote RJ
J Clin Oncol; 2004 Mar; 22(6):1007-13. PubMed ID: 14981105
[TBL] [Abstract][Full Text] [Related]
39. Prognostic role of the tumor-associated tissue inflammatory reaction in transitional bladder cell carcinoma.
Cai T; Nesi G; Boddi V; Mazzoli S; Dal Canto M; Bartoletti R
Oncol Rep; 2006 Aug; 16(2):329-34. PubMed ID: 16820911
[TBL] [Abstract][Full Text] [Related]
40. The prognostic value of p53, Ki-67 and matrix metalloproteinases MMP-2 and MMP-9 in transitional cell carcinoma of the renal pelvis and ureter.
Kamijima S; Tobe T; Suyama T; Ueda T; Igarashi T; Ichikawa T; Ito H
Int J Urol; 2005 Nov; 12(11):941-7. PubMed ID: 16351648
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
